UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia

Annals of internal medicine, 2016-04, Vol.164 (8), p.JC44

Aronson, Frederick R

2016

Volltextzugriff (PDF)

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2078-2085

2007

Volltextzugriff (PDF)

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Journal of immunotherapy (1997), 1994-10, Vol.16 (3), p.216-223

1994

Volltextzugriff (PDF)

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

Journal of clinical oncology, 1993-04, Vol.11 (4), p.661-670

1993

Volltextzugriff (PDF)

Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Chemo-Responsive Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.5468-5468

2005

Volltextzugriff (PDF)

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

Journal of clinical oncology, 1993-10, Vol.11 (10), p.1969-1977

1993

Volltextzugriff (PDF)

IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells

The Journal of immunology (1950), 1990-03, Vol.144 (6), p.2211-2215

1990

Volltextzugriff (PDF)

Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Blood, 2004-11, Vol.104 (11), p.5196-5196

2004

Volltextzugriff (PDF)

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

Journal of clinical oncology, 1992-02, Vol.10 (2), p.275-281

1992

Volltextzugriff (PDF)

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Journal of clinical oncology, 1994-08, Vol.12 (8), p.1553-1560

1994

Volltextzugriff (PDF)

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

Journal of clinical oncology, 1990-10, Vol.8 (10), p.1650-1656

1990

Volltextzugriff (PDF)

Inhibition of Interleukin-2-Induced Tumor Necrosis Factor Release by Dexamethasone: Prevention of an Acquired Neutrophil Chemotaxis Defect and Differential Suppression of Interleukin-2-Associated Side Effects

Blood, 1990-11, Vol.76 (10), p.1933-1940

1990

Volltextzugriff (PDF)

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity

Clinical cancer research, 1997-01, Vol.3 (1), p.39-46

1997

Volltextzugriff (PDF)

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma

Journal of immunotherapy (1997), 1994-02, Vol.15 (2), p.147-153

1994

Volltextzugriff (PDF)

Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens

Journal of surgical oncology, 1994-01, Vol.55 (1), p.7-13

1994

Volltextzugriff (PDF)

Summary statistics and treatment decisions

The American journal of medicine, 1993-03, Vol.94 (3), p.345-345

Aronson, Frederick R.

1993

Volltextzugriff (PDF)

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

Journal of clinical oncology, 1991-04, Vol.9 (4), p.641-648

1991

Volltextzugriff (PDF)

High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma

JNCI : Journal of the National Cancer Institute, 1990-07, Vol.82 (14), p.1202-1206

1990

Volltextzugriff (PDF)

Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma

JNCI : Journal of the National Cancer Institute, 1990-09, Vol.82 (17), p.1397-1402

1990

Volltextzugriff (PDF)

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma

Journal of immunotherapy (1997), 1994-01, Vol.15 (1), p.74-78

1994

Volltextzugriff (PDF)

Life-Threatening Bullous Skin Eruptions During Interleukin-2 Therapy

JNCI : Journal of the National Cancer Institute, 1991-01, Vol.83 (1), p.56-57

1991

Volltextzugriff (PDF)

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas

Journal of immunotherapy, 1991-06, Vol.10 (3), p.207-213

1991

Volltextzugriff (PDF)

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma

Journal of immunotherapy, 1991-06, Vol.10 (3), p.214

1991

Volltextzugriff (PDF)

Recombinant human GM-CSF in myelosuppression of chemotherapy (continued)

The New England journal of medicine, 1989-04, Vol.320 (14), p.939-940

1989

Volltextzugriff (PDF)

Insurance Coverage for Investigational Therapy

JNCI : Journal of the National Cancer Institute, 1990-09, Vol.82 (17), p.1434-1434

1990

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(40)
Reviews
(4)
Bücher
(1)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Humans
(33)
Male
(22)
Female
(21)
Middle Aged
(21)
Oncology
(19)
Biological And Medical Sciences
(18)
Adult
(17)
Medical Sciences
(17)
Aged
(15)
Interleukin-2 - Adverse Effects
(11)
Interleukin-2 - Therapeutic Use
(11)
Interleukin-2 - Administration & Dosage
(10)
Immunotherapy
(9)
Antineoplastic Agents
(8)
Pharmacology. Drug Treatments
(8)
Drug Evaluation
(7)
Melanoma - Therapy
(7)
Recombinant Proteins - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia

Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Chemo-Responsive Multiple Myeloma

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells

Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

Inhibition of Interleukin-2-Induced Tumor Necrosis Factor Release by Dexamethasone: Prevention of an Acquired Neutrophil Chemotaxis Defect and Differential Suppression of Interleukin-2-Associated Side Effects

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma

Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens

Summary statistics and treatment decisions

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma

Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma

Life-Threatening Bullous Skin Eruptions During Interleukin-2 Therapy

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma

Recombinant human GM-CSF in myelosuppression of chemotherapy (continued)

Insurance Coverage for Investigational Therapy

Suchergebnisse filtern